Simon Richardson
@simonrichardson.bsky.social
Clinician Scientist and Consultant Haematologist | Researches stem cell biology, epigenetics and drug discovery, specialising in B-ALL | Fellow St Catharine's College, Cambridge
Reposted by Simon Richardson
💙 Between now & the UCAS application deadline on 15 Oct, it’s worth checking if you're eligible for the Finlay Family Bursary, which covers all tuition fees & a living allowance for a St Catharine’s student from Scotland for all 3 or 4 years of an undergraduate degree: shorturl.at/K0RuE 3/3
The Finlay Family Bursary for Scottish undergraduates
We are proud to offer this bursary to encourage Scottish students to apply for, and take up, the offer of an undergraduate place at St Catharine’s – an opportunity which would normally involve greater financial cost than attending a Scottish university.
shorturl.at
August 5, 2025 at 9:15 AM
💙 Between now & the UCAS application deadline on 15 Oct, it’s worth checking if you're eligible for the Finlay Family Bursary, which covers all tuition fees & a living allowance for a St Catharine’s student from Scotland for all 3 or 4 years of an undergraduate degree: shorturl.at/K0RuE 3/3
Congrats! Really exciting work.
July 19, 2025 at 12:49 PM
Congrats! Really exciting work.
I feel a student granulomatous round of unknown aetiology coming on.
July 17, 2025 at 9:48 PM
I feel a student granulomatous round of unknown aetiology coming on.
Fabulous news Geula. Congratulations!! 🥂
July 7, 2025 at 8:27 PM
Fabulous news Geula. Congratulations!! 🥂
12/12 Special thanks to the patient donors and samples from VIVO Biobank and of course Brian Huntly & group 🤗 #CSCI @crukcamcentre.bsky.social | Work in my group is largely funded by Cancer Research UK #CRUK, Leukaemia UK
@leukaemiauk.bsky.social and the European Hematology Association. 🙏🏻
@leukaemiauk.bsky.social and the European Hematology Association. 🙏🏻
May 20, 2025 at 1:05 PM
12/12 Special thanks to the patient donors and samples from VIVO Biobank and of course Brian Huntly & group 🤗 #CSCI @crukcamcentre.bsky.social | Work in my group is largely funded by Cancer Research UK #CRUK, Leukaemia UK
@leukaemiauk.bsky.social and the European Hematology Association. 🙏🏻
@leukaemiauk.bsky.social and the European Hematology Association. 🙏🏻
11/12 Lots of thanks for help with this multidisciplinary project, including to stellar PhD Alicia Garcia-Gimenez and RA Jon Ditcham for all their hard work | to amazing collaborators @koulman.bsky.social @mitoredox.bsky.social @marcmansour.bsky.social
May 20, 2025 at 1:02 PM
11/12 Lots of thanks for help with this multidisciplinary project, including to stellar PhD Alicia Garcia-Gimenez and RA Jon Ditcham for all their hard work | to amazing collaborators @koulman.bsky.social @mitoredox.bsky.social @marcmansour.bsky.social
10/12 Excitingly, the CREBBP inhibitor Inobrodib has already been tested in combination with Venetoclax in AML, confirming safety. We therefore think this could be a novel, safe, oral approach that could complement current chemo- and immunotherapies, improving outcomes and reducing toxicity.
May 20, 2025 at 9:43 AM
10/12 Excitingly, the CREBBP inhibitor Inobrodib has already been tested in combination with Venetoclax in AML, confirming safety. We therefore think this could be a novel, safe, oral approach that could complement current chemo- and immunotherapies, improving outcomes and reducing toxicity.
9/12 The results almost perfectly replicated the findings in our genetic model, confirming marked sensitisation or synergy between CREBBP and BCL2 inhibitors in cell line and PDX models in vitro and in vivo.
May 20, 2025 at 9:43 AM
9/12 The results almost perfectly replicated the findings in our genetic model, confirming marked sensitisation or synergy between CREBBP and BCL2 inhibitors in cell line and PDX models in vitro and in vivo.